CBS 2019
CBSMD教育中心
中 文

Acute Coronary Syndrom

Abstract

Recommended Article

Precisely Tuned Inhibition of HIF Prolyl Hydroxylases Is Key for Cardioprotection After Ischemia Complete Versus Culprit-Only Lesion Intervention in Patients With Acute Coronary Syndromes Effect of Plaque Burden and Morphology on Myocardial Blood Flow and Fractional Flow Reserve Acute Microvascular Impairment Post-Reperfused STEMI Is Reversible and Has Additional Clinical Predictive Value: A CMR OxAMI Study The Prognostic Significance of Periprocedural Infarction in the Era of Potent Antithrombotic Therapy: The PRAGUE-18 Substudy Aggressive lipid-lowering therapy after percutaneous coronary intervention – for whom and how? Culprit lesion location and outcome in patients with cardiogenic shock complicating myocardial infarction: a substudy of the IABP-SHOCK II-trial Galectin-3 Levels and Outcomes After Myocardial Infarction: A Population-Based Study

Original Research2021 Jan 13.

JOURNAL:Circulation. Article Link

Clinical Efficacy and Safety of Alirocumab after Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial

GG Schwartz, PG Steg, ODYSSEY OUTCOMES Committees and Investigators et al. Keywords: PCSK9 inhibition; lipoprotein(a)

Full Text PDF